Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. (Q48967402)

http://europepmc.org/abstract/MED/26782663

17 February 2018

title

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. (English)

1 reference

http://europepmc.org/abstract/MED/26782663

17 February 2018

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Dana Horáková

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Alessandra Lugaresi

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Eugenio Pucci

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Suzanne J. Hodgkinson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Maria Trojano

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Steve Vucic

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

T Spelman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

L Mekhael

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

T Burke

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

E Havrdova

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

P Duquette

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

G Izquierdo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

F Grand'Maison

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

P Grammond

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

M Barnett

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

J Lechner-Scott

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

R Alroughani

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

F Granella

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

MSBase Study Group

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

publication date

19 January 2016

1 reference

http://europepmc.org/abstract/MED/26782663

17 February 2018

published in

European Journal of Neurology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

729-736

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States

11 June 2020

cites work

1 reference

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject

21 January 2018

1 reference

Factors that influence adherence with disease-modifying therapy in MS.

21 January 2018

1 reference

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

21 January 2018

1 reference

Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?

21 January 2018

1 reference

Tumefactive multiple sclerosis lesions under fingolimod treatment.

21 January 2018

1 reference

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

21 January 2018

1 reference

Relapses in patients treated with fingolimod after previous exposure to natalizumab

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

21 January 2018

1 reference

Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study

21 January 2018

1 reference

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

21 January 2018

1 reference

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

Comparative efficacy of switching to natalizumab in active multiple sclerosis

21 January 2018

1 reference

MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis

21 January 2018

1 reference

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

21 January 2018

1 reference

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

Risk of relapse phenotype recurrence in multiple sclerosis.

21 January 2018

1 reference

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

21 January 2018

1 reference

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Emerging oral therapies for multiple sclerosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ENE.12929

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782663%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference